Literature DB >> 20503409

Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers.

Mei Wu1, Zhi-Fen Wu, Devin T Rosenthal, Elliot M Rhee, Sofia D Merajver.   

Abstract

BACKGROUND: The 2 closely related small GTPases, RHOC and RHOA, are involved in mammary gland carcinogenesis; however, their specific roles in determining cancer cell adhesion and invasion have not been elucidated.
METHODS: RHOA and RHOC are highly homologous, thereby posing a major challenge to study their individual functions in cancer cells. By selectively knocking down these proteins, we have been able to alternatively inhibit RHOC and RHOA, while preserving expression of the other rho protein. Quantitative analyses of the growth patterns and invasion in the aggressive estrogen receptor negative cell lines MDA-231 and SUM149 were carried out on collagen I and Matrigel substrates.
RESULTS: RHOC, and not RHOA, modulates surface expression and colocalization of alpha2 and beta1 integrins in MDA-MB-231 on collagen I. Neither RHOC or RHOA affected integrin expression in the inflammatory breast cancer cell line SUM149, further highlighting the different regulation of adhesion and motility in inflammatory breast cancer.
CONCLUSIONS: This work shows that RHOC and RHOA play different roles in cell-matrix adhesion, motility, and invasion of MDA-MB-231 and reaffirms the crucial role of RHOC-GTPase in inflammatory breast cancer cell invasion. Copyright 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20503409     DOI: 10.1002/cncr.25181

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  35 in total

1.  LPS-induced nuclear translocation of RhoA is dependent on NF-κB in the human lung cancer cell line A549.

Authors:  Yan Tao; Yong-Chang Chen; Ting Lan; Hai Qian; Ying Wang; Lu Jiang
Journal:  Oncol Lett       Date:  2012-04-02       Impact factor: 2.967

2.  Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.

Authors:  Paula J Hurley; Robert M Hughes; Brian W Simons; Jessie Huang; Rebecca M Miller; Brian Shinder; Michael C Haffner; David Esopi; Yasunori Kimura; Javaneh Jabbari; Ashley E Ross; Nicholas Erho; Ismael A Vergara; Sheila F Faraj; Elai Davicioni; George J Netto; Srinivasan Yegnasubramanian; Steven S An; Edward M Schaeffer
Journal:  Cancer Res       Date:  2015-08-20       Impact factor: 12.701

3.  Spatial regulation of RhoC activity defines protrusion formation in migrating cells.

Authors:  Jose Javier Bravo-Cordero; Ved P Sharma; Minna Roh-Johnson; Xiaoming Chen; Robert Eddy; John Condeelis; Louis Hodgson
Journal:  J Cell Sci       Date:  2013-05-23       Impact factor: 5.285

4.  p38γ promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior.

Authors:  Devin T Rosenthal; Harish Iyer; Silvia Escudero; Liwei Bao; Zhifen Wu; Alejandra C Ventura; Celina G Kleer; Ellen M Arruda; Krishna Garikipati; Sofia D Merajver
Journal:  Cancer Res       Date:  2011-08-23       Impact factor: 12.701

5.  Bilobol inhibits the lipopolysaccharide-induced expression and distribution of RhoA in HepG2 human hepatocellular carcinoma cells.

Authors:  Jin Xu; Yueying Li; Xiaoming Yang; Yali Liu; Yongchang Chen; Min Chen
Journal:  Oncol Lett       Date:  2015-05-27       Impact factor: 2.967

6.  Rho isoform-specific interaction with IQGAP1 promotes breast cancer cell proliferation and migration.

Authors:  Darren E Casteel; Stephanie Turner; Raphaela Schwappacher; Hema Rangaswami; Jacqueline Su-Yuo; Shunhui Zhuang; Gerry R Boss; Renate B Pilz
Journal:  J Biol Chem       Date:  2012-09-19       Impact factor: 5.157

7.  RhoA and RhoC differentially modulate estrogen receptor α recruitment, transcriptional activities, and expression in breast cancer cells (MCF-7).

Authors:  Emilie Malissein; Elise Meunier; Isabelle Lajoie-Mazenc; Claire Médale-Giamarchi; Florence Dalenc; Sophie F Doisneau-Sixou
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-06       Impact factor: 4.553

Review 8.  A new class of protein cancer biomarker candidates: differentially expressed splice variants of ERBB2 (HER2/neu) and ERBB1 (EGFR) in breast cancer cell lines.

Authors:  Gilbert S Omenn; Yuanfang Guan; Rajasree Menon
Journal:  J Proteomics       Date:  2014-05-05       Impact factor: 4.044

9.  The SmgGDS splice variant SmgGDS-558 is a key promoter of tumor growth and RhoA signaling in breast cancer.

Authors:  Andrew D Hauser; Carmen Bergom; Nathan J Schuld; Xiuxu Chen; Ellen L Lorimer; Jian Huang; Alexander C Mackinnon; Carol L Williams
Journal:  Mol Cancer Res       Date:  2013-11-06       Impact factor: 5.852

10.  Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.

Authors:  Kevin P Williams; Jennifer L Allensworth; Shalonda M Ingram; Ginger R Smith; Amy J Aldrich; Jonathan Z Sexton; Gayathri R Devi
Journal:  Cancer Lett       Date:  2013-05-17       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.